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Chemotherapy is the first-line treatment for triple-negative breast 
cancer (TNBC), yet toxicity and resistance effects have been the current 
problems. Curcumin,a natural compound, has been reported to exert              
anti-proliferative effects on various cancer cells, including breast carcinoma 
cells. However, the β-diketone moiety influences the stability of curcumin. 
Curcumin analogs, pentagamavunon-0 (PGV-0), and pentagamavunon-1 
(PGV-1) were synthesized to improve the stability and activity of           
curcumin by modified the β-diketone moiety into mono-ketone pentanone. In 
this study, we evaluated the cytotoxicity, inhibition of cell cycle progression, 
and induction of apoptosis of curcumin and its analogs (PGV-0 and PGV-1) in 
murine triple-negative breast cancer 4T1 cell line. The cytotoxic evaluation 
was done by MTT assay, while apoptosis induction and cell cycle evaluation 
was performed by annexin V staining and detected by flow cytometry. 
Curcumin and its analogs, PGV-0, and  PGV-1, significantly inhibit the viability 
of 4T1 breast cancer cells with an IC50 value of 34.34µg/mL, 13.76µg/mL and 
38.21μg/mL, respectively. Apoptosis analysis with a dose of 10µg/mL and 
15µg/mL in 4T1 breast cancer cells showed that curcumin and its analogs 
effectively induce apoptotic in a dose-dependent manner. In cell cycle 
analysis using a dose of 15µg/mL, curcumin inhibited the cell cycle 
progression in the S phase, whereas PGV-0 and PGV-1 inhibited the cell cycle 
in the G2/M phase. It could be concluded that curcumin analogs, PGV-0 and 
PGV-1, have higher potential to be developed as anti-cancer agents by 
inducing cell cycle arrest and apoptosis in triple-negative breast cancer. 
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INTRODUCTION 
Breast cancer is one of the primary causes of 
death in women caused by cancer (Bray et al. 2018). 
Triple-negative breast cancer (TNBC), which 
accounts for 15–25% of breast tumors, has the 
worst prognosis because of this cancer insensitivity 
to traditional endocrine therapy and HER2-
targeted therapy and has the highest risk of relapse 
(Kim et al. 2013). Chemotherapy is the first line to 
TNBC therapy; however, its effectiveness is highly 
restricted due to problems of drug resistance and 
selectivity (Dm 2018; Isakoff 2010). Therefore, 
research on a new therapeutic agent that is 
effective and selective to treat TNBC is critically 
needed. Preclinical therapeutic studies with               
cell cycle inhibitors that target adaptive processes 
for cell proliferation as well as oncogenic signaling 
that affects the cell-cycle machinery have                  
shown antitumor responses (Cheok, 2012; Wang et 
al., 2011). Therefore, the development of               
natural compounds known to have 
chemotherapeutic properties and specific targets 
such as cell cycle checkpoints to induce arrest and 
apoptosis is a powerful strategy to treat cancer 
(Cheok 2012).  
The development of chemotherapeutic 
treatments for various diseases, such as cancer, is 
currently being explored (Xiao, Morris-Natschke, 
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and Lee 2016). Several natural products have 
played an important role in anti-cancer drug 
discovery (Khazir et al. 2013). Curcumin is a 
potential natural compound that has several 
biological activities such as antioxidant activity, 
anti-inflammatory (Atsumi et al. 2005; Motterlini et 
al. 2000), and anti-cancer (Aggarwal et al. 2006; 
Bar-Sela, Epelbaum, and Schaffer 2010; Zhu and Bu 
2017). However, the presence of β-diketone moiety 
influences the stability of curcumin (Vyas et al. 
2013). Therefore, structural modification is a 
strategy to improve the stability and solubility of 
curcumin. The improvement of its stability and 
solubility is expected to increase the 
pharmacological effect and decrease the 
toxicological effect of the compounds (Bevan, 
Ryder, and Shaw 1995; Guo 2017). PGV-0 and PGV-
1 are monoketone curcumin analogs with cyclo-
pentanone structure modification (Sardjiman et al. 
1997). Although several studies of PGV-0, and          
PGV-1, showed cytotoxic activity on several line 
cells such as MCF 7 (Meiyanto, 2011) and WiDr 
(Ikawati and Septisetyani 2018), their activity on 
4T1 triple-negative breast cancer cells have not 
been elucidated. Thus, in this study, we evaluate the 
effects of curcumin analogs, PGV-0 and PGV-1, 
focusing on their activity to induce apoptosis and 
cell cycle arrest in the 4T1 highly metastatic, triple-
negative breast cancer cells. 
 
MATERIALS AND METHODS 
Curcumin (Sigma), PGV-0 dan PGV-1 ware 
synthesized by Curcumin Research Center (CRC), 
Faculty of Pharmacy,  Universitas Gadjah Mada. 
Each compound was dissolved in DMSO (Sigma). 3-
(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazo-
leium bromide (MTT) was obtained from Sigma. 
 
Cell line and cell culture 
The 4T1 cells were obtained from ATCC.        
The cells were cultured in RPMI medium 
supplemented with 10% FBS (Gibco), 150 IU/mL 
penicillin, and 150μg/mL streptomycin (Gibco). 
Cultured cells were maintained in a CO2 incubator 
at 37ᵒC. 
 
Cytotoxic assay 
Cytotoxic evaluation was conducted by using 
MTT Assay. This assay was carried out triplicate. 
The 4T1 cells were seeded in a 96-well plate (1x104 
cells/well). A series of concentrations of curcumin, 
PGV-0, or PGV-1 was diluted in the culture medium. 
After 24h of incubation, the medium was removed, 
and cells were washed using phosphate buffer 
saline (PBS) (Sigma). 5mg/mL of 3-(4,5-
Dimethylthiazol-2-yl)- 2,5-Diphenyltetrazolium 
Bromide (MTT) reagent (Sigma) in PBS was diluted 
in RPMI medium, and 100 μL of reagent was added 
to each well. After 3 hours of incubation, the 
reaction was stopped by the addition of 100 μL of 
Sodium Dodecyl Sulfate (SDS) 10% in HCl 0.01 N, 
and incubated overnight at room temperature in a 
dark place. The absorbance was measured using a 
microplate reader at λ 595 nm. The percentage of 
cell viability was defined as (absorbance of treated 
cells - absorbance of blank)/(absorbance of control 
- absorbance of blank) x 100%, and were used to 
calculate IC50 values by a linear regression analysis 
between cell viability (%, y axis) vs log 
concentration (µg/mL, x axis) (Doyle and Griffiths 
2000). 
 
Apoptosis assay 
Apoptosis assay was performed by using 
Annexin V-FITC/PI staining (BD Bioscience, 
Catalog no. 556547) flow cytometry. The cells were 
seeded in a 6-well plate at a density of 5x105 
cells/well, respectively, and treated with curcumin 
and its analogs at 15 μL/mL for 24h.  Then, the cells 
were trypsinized with 0.25% trypsin, centrifuged, 
and washed with cold PBS and resuspended                       
in Annexin V binding buffer at a concentration                
of 0.25-1.0x107cells/mL. Afterward, 100μL of cell 
suspension was transferred in a test tube followed 
by the addition of FITC annexin V and 10μL of                  
PI solution. Cells were vortexed and incubated for 
10 minutes at room temperature in the dark,              
then 400 ul annexin V binding buffer was added               
to each tube. Flow cytometer (BD Bioscience, US) 
was used to analyze 50,000 cells, and data            
were analyzed by using the Graphpad Prism 6.0 
program. 
 
Cell cycle assay 
Cell cycle analysis was performed by using 
propidium iodide (PI)-staining flowcytometry. 
Cells (5x104 cells/well in 6-well plate) were seeded 
in a 6-well plate and incubate overnight. The media 
was replaced with the fresh medium that contains 
curcumin and its analogs at 10μL/mL and 15μL/mL. 
Treated-cells were washed with cold PBS, fixed 
with 75% ethanol and then incubated overnight at 
-20ᵒC. The fixed cells were incubated with 
propidium iodide (PI) solution in the dark at room 
temperature for 30min. The samples were 
immediately measured by (BD Biosciences, US).  
The data obtained were analyzed by using the 
Graphpad Prism 6.0 program.  
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RESULTS AND DISCUSSION 
Curcumin and its analogs inhibit cancer cell 
viability on the 4T1 breast cancer cells. 
The effect of curcumin and its analogs 
(Figure 1) on the viability of the 4T1 breast cancer 
cell was measured by MTT assay. Data illustrates 
that the treatment of curcumin, PGV-0, and PGV-1 
significantly inhibits 4T1 breast cancer cell  
viability in a dose-dependent manner (Figure 2). 
The IC50 value of curcumin, PGV-0, and PGV-1 for 
24h in the 4T1 breast cancer cells are 34.34μg/mL, 
13.76μg/mL, and 38.21μg/mL, respectively. 
 
Exposure to curcumin and its analogs 
stimulates cell apoptosis of 4T1 breast cancer 
cells. 
Annexin V-FITC/PI double staining was 
performed to confirm whether the effects of 
curcumin and its analog on the cytotoxicity of 4T1 
cells were related to apoptosis. Curcumin, PGV-0, 
and PGV-1 treatments at 10μg/mL for 24h show 
that the apoptotic cell population increase from 
0.23% to 0.94%, 1%, and 2.38%, respectively, 
compared with the untreated cell population 
(Figure 4). From this result, it shows that PGV-1 can 
significantly induce apoptosis. However, the 
percentage of the late apoptotic cell at 10μg/mL 
was relatively low at all treatment but increased to 
5.19%, 6.79%, and 4.81%, respectively, at 
15μg/mL. This result shows that curcumin, PGV-0, 
and PGV-1 can significantly increase apoptosis with 
dosage 15μg/mL. From this result, we can conclude 
that curcumin and its analogs effectively induce 
apoptotic occurrence in a dose-dependent manner. 
PGV-0 and PGV-1 show higher apoptotic effects in 
4T1 breast cancer cells compared to curcumin. 
PGV-1 appears better in inducing the early 
apoptosis phase than curcumin. In contrast, PGV-0 
shows more significant effect in the late apoptosis 
phase than curcumin.  
 
Curcumin and its analog induce cell cycle arrest 
on the 4T1 breast cancer cells. 
To investigate whether the increased of         
apoptosis is related to cell cycle arrest, treated         
cells were analyzed by flow cytometry at the 
different phases of the cell cycle (sub-G1, G1, S,          
and G2/M). Curcumin treatment showed                  
that the percentage of 4T1 breast cancer cells            
in   the   S   phase    was   increased   (Figure  3  (B)).  
 
Curcumin 
 
PGV-0  
PGV-1 
Figure 1. Structure of Curcumin and its analog  
 
      
   a             b 
 
Figure 2. Cytotoxic effect of curcumin and its analog on 4T1 cells. An in vitro study was initiated by treating 
4T1 breast cancer cell with increasing doses of curcumin, PGV-0 and PGV-1 for 24h. (A) The viability of the 
curcumin and its analog-treated cell was measuring using MTT assay. (B) The histograms of viability cells. 
Vertical bars represent the standard deviation of means (SD) (n= 3). 
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Figure 3. Effects of curcumin, PGV-0, and PGV-1 treatment on cell cycle in 4T1 cells. (A) The 4T1 breast 
cancer cell treated with 15μg/mL concentration of curcumin and it analog for 24h and stained with PI to 
analyze cell distribution by flow cytometry.  (B) The histograms of the cell cycle. Vertical bars represent the 
standard deviation of means (SD) (n= 3). 
 
 
 
a 
 
b 
 
Figure 4. Effects of curcumin, PGV-0, and PGV-1 treatment on apoptosis in 4T1 cells. (A) The cells were 
treated with 10 μg/ml  and 15 μg/ml curcumin, PGV-0, and PGV-1, stained with Annexin V, PI. After staining, 
flow cytometry was performed to determine apoptosis. (B) The histograms of the apoptotic cells. Total 
apoptotic cells significantly increased following exposure to 15 μg/ml, compared with 10 μg/ml after 24 
hours. Vertical bars represent the standard deviation of means (SD) (n= 3). *p < 0.05.  
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On the contrary, PGV-0 and PGV-1 treatment 
increased cell accumulation in the G2/M phase. 
These results suggest that curcumin and its analogs 
inhibit the cell cycle of 4T1 breast cancer cells 
through different mechanisms. Curcumin induces 
cell cycle arrest at the S phase. In addition, PGV-0 
and PGV-1 induce G2/M phase cell cycle arrest. 
Several studies on mono carbonyl curcumin 
analogs reported that they have been more potent 
than curcumin in MDA-MB231, DU145, Hela, K562 
dan MCF7 cell (Adams et al., 2005; Zamrus et al., 
2018; Zhang et al., 2015). These results could be 
due to the chelating and enolization effects of 
hydrogen bonding that caused a strong binding 
with the receptor. Moreover, mono-carbonyl 
curcumin analog has a bis-enone conjugated 
system that more selective to bind with the 
targeted nucleophile (Zamrus et al. 2018b). On the 
other hand, modification of β-diketone into mono-
ketone could increase the stability, solubility, and 
biodistribution of curcumin (Xia et al. 2014).            
From Figure 2, we can see that PGV-0 has higher 
cytotoxic activity than curcumin and PGV-1 in 4T1 
cells. In this respect, the curcumin analog with 
mono-carbonyl structure could be potential                       
to be developed as a new anti-cancer drug                      
and considered as a remarkable approach for 
improvement of curcumin’s bioavailability 
problems.  
The inhibitory effect of curcumin and its 
analogs on the cancer cell line were due to its ability 
to induce cell cycle arrest (Lee et al., 2009; 
Meiyanto, 2011). Cell cycle checkpoint is the 
surveillance mechanism of controlling abnormal 
cell conditions, including cancer. In the cell cycle 
phase, an abnormal cell could repair by cell cycle 
arrest or apoptosis. During the early apoptosis, 
phosphatidylserine was translocated from the 
plasma membrane to the outer side. Curcumin 
induces cell cycle arrest at S phase. In addition, 
PGV-0 and PGV-1 induce G2/M phase cell cycle 
arrest. The G2 checkpoint prevents cells from 
entering mitosis when DNA is damaged, providing 
an opportunity for repair and stopping the 
proliferation of damaged cells (Khodjakov and 
Rieder 2009). The eukaryotic cell cycle progression 
is regulated by the coordinated activity of cyclin-
dependent kinase (Cdk) and cyclin complexes. It is 
known that the G2/M transition is dependent 
mainly on the cyclin B/Cdk-1 activity (Graña and 
Reddy 1995). Literature shows that p53 is one of 
the most important regulators in mediating growth 
arrest and apoptosis induced by chemotherapeutic 
compounds. The active p53 can transcriptionally 
increase the expression levels of its target genes, 
especially p21. This protein, in turn, stops the cell 
cycle progression, by blocking the function of 
cyclin-Cdk complexes, to repair damages induced 
by various stresses. Once the damages are unable 
to be repaired, p53 activates the transcription of 
various pro-apoptotic genes, including Bax, and 
suppresses transcription of various anti-apoptotic 
genes, such as Bcl-2 (Robbins and Zhao 2012).  
 A recent study reports that curcumin 
induced G1/S and G2/M cell cycle arrest in human 
osteosarcoma (HOS) cell (Lee, Lee, and Kim 2009b). 
Moreover, curcumin induces G2/M arrest in human 
pancreatic cell and induces G0/G1 arrest in 
mesothelioma cell (Mayol et al. 2015). PGV-1 
inhibits cell growth of breast cancer MCF7 and 
T47D cell line by inducing G2/M arrest, while PGV-
0 induces G2/M arrest in MCF7 cell line (Meiyanto 
2011b; Meiyanto et al. 2018). Furthermore, 
curcumin analog of A501 and WZ35 induces G2/M 
cell cycle arrest in non-small lung cancer cells, and 
prostate cancer cells (Xia et al., 2014; Zhang et al., 
2015)  and EF24 also induce G2/M arrest in MAD-
MB cell line by increasing level of ROS, while 
simultaneously decrease the cellular level of GSH 
(Adams et al. 2005b). Results of this present study 
was supported by a previous study that 
demonstrated G2/M cell cycle arrest upon PGV-1 
treatment ( 2 and 4 μM) in 4T1 cells (Meiyanto et al. 
2019). Moreover, the same author showed S phase 
arrest upon curcumin treatment in concentration 
of 25 μM in 4T1 cells. Taken together, the 
mechanism of curcumin and PGV-1 in cell cycle 
arrest is occurred in concentration independent 
manner.  
 Cell cycle checkpoint is the surveillance 
mechanism of controlling abnormal cell conditions, 
including cancer. In the cell cycle phase, an 
abnormal cell could repair by cell cycle arrest or 
apoptosis. Our results suggest that curcumin and 
its analogs effectively induce apoptosis in a dose-
dependent manner. PGV-0 and PGV-1 show a 
higher apoptotic effect in 4T1 breast cancer cells 
compared to curcumin. PGV-1 appears better to 
inducing apoptosis in an early stage. It defines by 
changes in nuclear morphology follow a little later, 
as does as cell shrinkage. In contrast, PGV-0 shows 
a more significant effect in inducing late apoptosis 
and causes cells to undergo necrosis. However, the 
detailed mechanism of action of PGV-0 and PGV-1 
is not clearly elucidated. Several recent studies 
show that curcumin induces apoptosis in several 
adenocarcinoma cell lines by decreasing the anti-
apoptosis like inhibitor of apoptotic protein (IAP), 
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X-chromosome-linked IAP, Bcl-2, Bcl-xL, and Bfl-
1/A1. Curcumin also inhibits NF-kB activation and 
NF-kB-regulated gene expression through 
inhibition of IKK and Akt activation (Aggarwal 
2005). Furthermore, curcumin decreases 
methylglyoxal-induced ROS formation, which 
would cause apoptosis in human hepatoma G2 cells 
(Chan, Wu, and Hsuuw 2005). Another study 
revealed that PGV-0 and PGV-1 induce apoptosis in 
MCF7 cell line (Meiyanto 2011b), and T47D breast 
cancer cell line through induction Caspase 3 
(Meiyanto et al. 2018). Therefore, PGV-0 and PGV-
1 might induce apoptosis through the inhibition of 
NF-kB activation and regulation of BCL protein in a 
triple-negative breast cancer cell. Some limitations 
should be noted. We used only one cell line, 4T1 
murine cell line. So, experiments on normal cells 
and human TNBC cells have not been conducted. 
Further exploration is needed to elucidate their 
specific mechanism of actions. 
 
CONCLUSION 
Curcumin analogs, PGV-0 and PGV-1, have 
the potency to be developed as chemotherapeutic 
agents for triple-negative breast cancer through 
inhibition of tumor growth by inhibit the cell cycle 
progression and induce apoptosis. Hence, their 
molecular mechanism of cell cycle arrest and 
apoptotic induction in triple-negative breast cancer 
needs to be further explored. 
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